Estimating the efficacy and efficiency of cascade genetic screening

American Journal of Human Genetics

Volumn 69, Issue 2, 2001, Pages 361-370

  Krawczak, Michael ^a   Cooper, David N ^a   Schmidtke, Jörg ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ARTICLE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; MASS SCREENING; POPULATION GENETICS; POPULATION RISK; PRIORITY JOURNAL;

EID: 0034928709     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/321973     Document Type: Article

References (28)

1. Should we genetically test everyone for haemochromatosis?
2. Views of a general population on mass screening for colorectal cancer: The Burgundy Study
3. Hereditary hemochromoatosis
4. Genetics of iron storage and hemochromatosis
5. Population screening for haemochromatosis: Expectations based on a study of relatives of symptomatic probands
6. Population screening for haemochromatosis: A unifying analysis of published intervention trials
7. Implications of preventive health behaviour for cervical and breast cancer screening programmes: A review
8. Screening for factor V Leiden mutation before prescribing combination oral contraceptives
9. The frequency of consanguineous marriage among British Pakistanis
10. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
11. Screening practices for mutations in the CFTR gene ABCC7
12. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2
13. Cascade testing for the identification of carriers of cystic fibrosis
14. Initial sequencing and analysis of the human genome
15. Active cascade screening for cystic fibrosis
16. A population-based study of the clinical expression of the hemochromatosis gene
17. A commentary on the NIH consensus development statement 'Genetic Testing for Cystic Fibrosis'
18. Cost-effectiveness of population-based genetic hemochromatosis screening
19. Neonatal screening for cystic fibrosis in Brittany, France: Assessment of 10 years' experience and impact on prenatal diagnosis
20. Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency
21. Active cascade testing for carriers of cystic fibrosis gene
22. Screening for cystic fibrosis should begin with cascade screening
23. A simple genetic test identifies 90% of UK patients with haemochromatosis
24. The sequence of the human genome
25. Colorectal cancer and its prevention: Prevalence of beliefs, attitudes, intentions and behaviour
26. Screening for cystic fibrosis and its evaluation
27. Efficacy of cascade testing for fragile X syndrome